INVESTOR PRESENTATION OF FREDUN PHARMACEUTICALS LIMITED
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals shared an investor presentation covering its diversified pharma business spanning generics, pet care (Freossi), nutraceuticals (Fredun Nutrition), cosmeceuticals (BeautyFred, Bird n Beauty), and mobility products. The company has 697 registered products across 52 countries and 1,200+ products under registration, with revenue mix at 83% domestic and 17% exports. Revenue from Operations grew from Rs. 113 Cr in FY20 to Rs. 454 Cr in FY25, while EBITDA margins expanded from 7.8% to 12.1% and ROCE jumped from 11.4% to 31.8%. Management highlighted new growth areas including dental care, gym supplements, fragrances, large animal healthcare, and India's first dedicated pet diagnostic centre. Key upcoming plans include entering Pan West Zone for nutrition by FY26, finalising contracts with 3 MENA countries, and launching 50 new OEM products. Note: Financial costs rose sharply from Rs. 4.4 Cr (FY20) to Rs. 22.4 Cr (FY25), and current borrowings spiked to Rs. 156.8 Cr.
Shares a clear growth story with 4x revenue scaling and improving margins, but rising debt and finance costs may temper near-term enthusiasm. Management's explicit guidance on margin expansion through new-age products and diversification into pet care, nutraceuticals, and diagnostics could be a positive trigger for the stock.